Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$13.60
-3.5%
$22.31
$13.55
▼
$28.23
$1.54B1.83.76 million shs2.26 million shs
Prothena Corporation plc stock logo
PRTA
Prothena
$8.40
+0.6%
$8.45
$7.70
▼
$11.80
$428.77M-0.2467,873 shs566,979 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$14.17
-2.5%
$18.04
$14.07
▼
$24.68
$1.56B0.451.81 million shs2.07 million shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$8.87
-3.1%
$11.00
$5.45
▼
$14.38
$1.57B1.73.10 million shs1.89 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-0.98%-13.66%-43.44%-47.87%+11.20%
Prothena Corporation plc stock logo
PRTA
Prothena
+1.09%-4.35%-1.53%-7.53%-19.40%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-1.62%-12.89%-18.05%-24.40%-16.69%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-1.08%-30.31%-10.38%-0.65%+66.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$13.60
-3.5%
$22.31
$13.55
▼
$28.23
$1.54B1.83.76 million shs2.26 million shs
Prothena Corporation plc stock logo
PRTA
Prothena
$8.40
+0.6%
$8.45
$7.70
▼
$11.80
$428.77M-0.2467,873 shs566,979 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$14.17
-2.5%
$18.04
$14.07
▼
$24.68
$1.56B0.451.81 million shs2.07 million shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$8.87
-3.1%
$11.00
$5.45
▼
$14.38
$1.57B1.73.10 million shs1.89 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-0.98%-13.66%-43.44%-47.87%+11.20%
Prothena Corporation plc stock logo
PRTA
Prothena
+1.09%-4.35%-1.53%-7.53%-19.40%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-1.62%-12.89%-18.05%-24.40%-16.69%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-1.08%-30.31%-10.38%-0.65%+66.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.87
Moderate Buy$34.43153.15% Upside
Prothena Corporation plc stock logo
PRTA
Prothena
2.67
Moderate Buy$20.00138.10% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.00
Hold$23.8067.96% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.78
Moderate Buy$22.57154.47% Upside

Current Analyst Ratings Breakdown

Latest PRTA, SRPT, NRIX, and VIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/19/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Boost Price TargetNeutral$20.00 ➝ $22.00
11/12/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell (E+) ➝ Sell (D)
11/10/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell ➝ Hold$14.00 ➝ $18.00
11/10/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Boost Price TargetOverweight$25.00 ➝ $28.00
11/9/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Reiterated RatingBuy$22.00
11/6/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Set Price Target$18.00
11/6/2026
Prothena Corporation plc stock logo
PRTA
Prothena
Initiated CoverageStrong-Buy
11/6/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Boost Price TargetSector Perform$17.00 ➝ $18.00
11/5/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Boost Price TargetBuy$18.00 ➝ $20.00
11/4/2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Lower Price TargetHold ➝ Overweight$25.00 ➝ $20.00
11/4/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
UpgradeStrong Sell ➝ Hold
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$83.98M17.69N/AN/A$5.29 per share2.57
Prothena Corporation plc stock logo
PRTA
Prothena
$9.68M44.56N/AN/A$5.24 per share1.60
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20B0.69N/AN/A$14.26 per share0.99
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$68.56M22.16N/AN/A$5.23 per share1.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$264.46M$2.315.89N/AN/A42.01%49.34%38.61%1/27/2027 (Estimated)
Prothena Corporation plc stock logo
PRTA
Prothena
-$244.09M-$0.48N/AN/A4.37-45.44%-9.98%-9.08%N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$1.37N/A13.120.25-5.86%-0.20%-0.09%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$437.99M-$1.26N/AN/AN/AN/A-21.38%-16.97%N/A

Latest PRTA, SRPT, NRIX, and VIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Prothena Corporation plc stock logo
PRTA
Prothena
-$0.2271-$0.32-$0.0929-$0.32$9.58 million$0.62 million
11/5/2026Q3 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.0790$0.13+$0.0510-$0.27$352.20 million$381.35 million
11/4/2026Q3 2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.7493-$0.57+$0.1793-$0.57$0.98 million($0.19) million
10/13/2026Q3 2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.6009$4.73+$5.3309$4.73$24.35 million$673.06 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A
Prothena Corporation plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
8.44
8.44
Prothena Corporation plc stock logo
PRTA
Prothena
N/A
23.95
23.95
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.46
3.46
2.13
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.30
6.30

Institutional Ownership

CompanyInstitutional Ownership
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
Prothena Corporation plc stock logo
PRTA
Prothena
97.08%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
6.70%
Prothena Corporation plc stock logo
PRTA
Prothena
10.40%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6.90%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
357109.25 million101.93 millionOptionable
Prothena Corporation plc stock logo
PRTA
Prothena
6751.35 million46.01 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
835107.24 million99.84 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
367171.27 million166.30 millionOptionable

Recent News About These Companies

Vir Biotechnology stock: USD 150 million offering priced
Why is Vir Biotechnology stock falling Friday?
Vir Biotechnology stock tumbles on $150M share offering
HC Wainwright Has Optimistic Opinion of VIR FY2026 Earnings
Vir Biotechnology Announces Proposed Public Offering
TD Cowen Reaffirms Their Buy Rating on Vir Biotechnology (VIR)
Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
What is HC Wainwright's Estimate for VIR FY2026 Earnings?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Nurix Therapeutics stock logo

Nurix Therapeutics NASDAQ:NRIX

$13.60 -0.50 (-3.55%)
Closing price 04:00 PM Eastern
Extended Trading
$13.39 -0.21 (-1.54%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Prothena stock logo

Prothena NASDAQ:PRTA

$8.40 +0.05 (+0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$8.40 -0.01 (-0.06%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$14.17 -0.36 (-2.48%)
Closing price 04:00 PM Eastern
Extended Trading
$14.25 +0.08 (+0.56%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$8.87 -0.28 (-3.06%)
Closing price 04:00 PM Eastern
Extended Trading
$8.87 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.